Plasma CD93 concentration
is a potential novel biomarker for coronary artery disease
BACKGROUND:
A common nonsynonymous single nucleotide
polymorphism (SNP) in the CD93 gene
(rs3746731, Pro541Ser) has been associated with risk of coronary
artery disease (CAD).CD93 is a
transmembrane glycoprotein, which is detectable in soluble form in
human plasma. We investigated whether the concentration of soluble CD93 in plasma is
related to risk of myocardial infarction (MI) and CAD, using a
case-control study of premature MI (n = 764) and a nested
case-control analysis of a longitudinal cohort study of 60-year-old
subjects (analysis comprising 844 of 4232 subjects enrolled at
baseline). In addition, SNPs in the CD93 gene were
studied in relation to plasma CD93 concentration
and mRNA expression.
MATERIALS AND METHODS: A sensitive and specific enzyme-linked immunosorbent assay was established for determination of the plasma CD93concentration. Subjects were divided into three groups according to tertiles of the distribution of CD93 concentration. Lower odds ratios for risk of MI and incidence of CAD were observed in the middle CD93 tertile (142-173 μg L(-1) ): odds ratio (95% confidence interval), 0.69 (0.49-0.97) and 0.61 (0.40-0.94), respectively. These associations were independent of traditional CAD risk factors. The minor allele of a SNP in the 3' untranslated region of CD93 (rs2749812) was associated with increased plasma CD93 concentrations (P = 0.03) and increased CD93 mRNA expression levels (P = 0.02).
he results of the present study suggest
that the concentration of soluble CD93 in plasma is a
potential novel biomarker for CAD, including MI.
Mälarstig A
et al. J Intern Med 2011 Sep;270(3):229-36
Human Soluble CD93 ELISA Kit
Code No.: SK00399-01
Size: 96T
Price: $360.00 USD
Standard Range:1.56 - 100 ng/mL
Sensitivity:300 pg/mL
Sample Type: EDTA plasma
Dilution factor: 2
Sample Volume: 100 uL
IntraCV: 4-6%
InterCV: 8-12%
Protocol: PDF